Not applicableStudy completedNCT04756921What this trial is testing18F-FDG Uptake Heterogeneity Predicts Pyrotinib ResponseWho this might be right forHER2-positive Breast Cancer Biyun Wang, MD 30
Testing effectiveness (Phase 2)UnknownNCT04997798What this trial is testingDalpiciclib in Combination With Exemestane and Trastuzumab Plus Pyrotinib in Early Triple Positive Breast CancerWho this might be right forBreast CancerEstrogen Receptor Positive TumorHER2-positive Breast Cancer First Affiliated Hospital of Zhejiang University 30
Testing effectiveness (Phase 2)UnknownNCT04293276What this trial is testingStudy to Evaluate the Efficacy and Safety of SHR6390 Combined With Pyrotinib in HER2+ Advanced Breast CancerWho this might be right forMetastatic Breast Cancer Henan Cancer Hospital 41
Testing effectiveness (Phase 2)UnknownNCT04605575What this trial is testingPyrotinib Plus Vinorelbine in Participants With HER2-positive Previously Treated Locally Advanced or Metastatic Breast CancerWho this might be right forBreast CancerPyrotinibBreast Diseases+2 more Sun Yat-sen University 208
Early research (Phase 1)Study completedNCT04479891What this trial is testingEffect of Itraconazole on the Pharmacokinetics of Pyrotinib in Healthy SubjectsWho this might be right forHealthy Subjects Jiangsu HengRui Medicine Co., Ltd. 18
Testing effectiveness (Phase 2)UnknownNCT04236310What this trial is testingNeoadjuvant SHR6390 in Combination With Anastrozole, Pyrotinib, and Trastuzumab in Patients With ER+/HER2+ Breast Cancer.Who this might be right forBreast CancerHER2-positive Breast CancerER-positive Breast Cancer Ruijin Hospital 37
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06973525What this trial is testingThis Study Aims to Optimize Neoadjuvant Therapy for HER2-positive Breast Cancer by Implementing a Dynamic Monitoring-guided Treatment Strategy.Who this might be right forHER2-positive Breast Cancer Hebei Medical University Fourth Hospital 30
Testing effectiveness (Phase 2)UnknownNCT04681911What this trial is testingInetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast CancerWho this might be right forBreast Cancer Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 71
Testing effectiveness (Phase 2)Looking for participantsNCT04481932What this trial is testingTrastuzumab Combined With Pyrrolidine and Chemotherapy for Locally HER2 Positive Breast CancerWho this might be right forHER2-positive Breast Cancer Peking University 104
Testing effectiveness (Phase 2)UnknownNCT03919253What this trial is testingPyrotinib in Combination With Nab-paclitaxel in Patients With HER2-positive Advanced Breast Cancer: an Exploratory StudyWho this might be right forHER2-positive Breast Cancer Hebei Medical University Fourth Hospital 80
Testing effectiveness (Phase 2)UnknownNCT05020964What this trial is testingScreening Plasma HER2 Amplication by Digital PCR in Advanced Breast Cancer Patients Treated With Trastuzumab and PyrotinibWho this might be right forAdvanced Breast Cancer Chinese Academy of Medical Sciences 68
Testing effectiveness (Phase 2)UnknownNCT04785729What this trial is testingAlmonertinib Combined With Pyrotinib in the Treatment of Advanced NSCLC Patients With HER-2 Amplification/Mutation After EGFR-TKI ResistanceWho this might be right forSafety Sun Yat-sen University 36
Testing effectiveness (Phase 2)UnknownNCT04001621What this trial is testingPyrotinib in Combination With Capecitabine in Patients With Trastuzumab-resistant HER2-positive Advanced Breast CancerWho this might be right forMetastatic Breast Cancer Fudan University 100
Large-scale testing (Phase 3)Looking for participantsNCT07615751What this trial is testingPyrotinib and Trastuzumab Combined With Dalpiciclib Versus Combined With Docetaxel in Advanced HER2-Positive Breast CancerWho this might be right forBreast Cancer Fudan University 502
Testing effectiveness (Phase 2)Looking for participantsNCT07616453What this trial is testingEfficacy and Safety of Culmerciclib Plus Aromatase Inhibitors in a Response-Adapted Neoadjuvant Strategy for Highly Proliferative ER-Positive/HER2-Negative Breast CancerWho this might be right forHR+/HER2- Early Breast Cancer Second Affiliated Hospital, Zhejiang University, School of Medicine 45
Testing effectiveness (Phase 2)Study completedNCT03735966What this trial is testingNeoadjuvant Study of Pyrotinib and Trastuzumab Plus Docetaxel and Carboplatin in HER2 Positive Breast Cancer Patients.Who this might be right forHER2 Positive Breast Cancer Henan Cancer Hospital 75
Testing effectiveness (Phase 2)Looking for participantsNCT07014410What this trial is testingPyrotinib Combined With Dalpiciclib Combined With Letrozole in ER-positive and HER2-positive Advanced Breast CancerWho this might be right forBreast Cancer Zhejiang Cancer Hospital 63
Not applicableUnknownNCT05030519What this trial is testingDiarrhea and Intestinal Flora Changes Caused by Pyrotinib in Breast CancerWho this might be right forBreast Cancer Zhejiang Cancer Hospital 50
Not applicableLooking for participantsNCT06234137What this trial is testingA Prospective, Open, Multicenter Single-arm Clinical Studie of Docetaxel, Carboplatin Combined With Inetetamab and Pyrotinib in the Treatment of Local-advanced HER2-positive Breast CancerWho this might be right forBreast Neoplasm Female Wang Ouchen 154
Testing effectiveness (Phase 2)UnknownNCT05800756What this trial is testingPyrotinib Combined With Trastuzumab,Dalpiciclib and Letrozole for HR+/HER2+ Breast CancerWho this might be right forBreast Cancer Yantai Yuhuangding Hospital 30